Tag Archives: Yigal Nochomovitz

Portola Pharma (PTLA) Gets a Buy Rating from Citigroup

Citigroup analyst Yigal Nochomovitz maintained a Buy rating on Portola Pharma (PTLA – Research Report) today and set a price target of $44.00. The company’s shares closed last Monday at $27.03. According to TipRanks.com, Nochomovitz is a 4-star analyst with

Analysts Offer Insights on Healthcare Companies: Loxo Oncology (NASDAQ: LOXO) and Amgen Inc (NASDAQ: AMGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Loxo Oncology (NASDAQ:LOXO) and Amgen Inc (NASDAQ:AMGN) with bullish sentiments. Loxo Oncology (LOXO) Citigroup analyst Yigal Nochomovitz maintained a Buy rating on

Analysts Offer Insights on Healthcare Companies: Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Puma Biotechnology (NYSEArca: PBYI) and Bioverativ Inc (NASDAQ: BIVV). Puma Biotechnology (NYSEArca: PBYI) In a report released today, Yigal Nochomovitz from Citigroup maintained

Portola Pharma Received its Third Buy in a Row

After Oppenheimer and Cowen & Co. assigned a Buy rating to Portola Pharma in the last month, the company received another Buy, this time from Citigroup. Analyst Yigal Nochomovitz reiterated a Buy rating on Portola Pharma (NASDAQ: PTLA) today and

Portola Pharma Got Some Good News

In a report released today, Yigal Nochomovitz from Citigroup upgraded Portola Pharma (NASDAQ: PTLA) to Buy. The company’s shares opened today at $22.89. According to TipRanks.com, Nochomovitz is ranked 0 out of 5 stars with an average return of -7.8%

Citigroup Believes LXRX Won’t Stop Here

Citigroup analyst Yigal Nochomovitz maintained a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX) today and set a price target of $25. The company’s shares closed last Friday at $17.85, close to its 52-week high of $19.19. According to TipRanks.com, Nochomovitz